In patients with melanoma, the biomarker predicting response to PD‐1/PD‐L1 inhibitors was studied using flow cytometry analysis, and it was shown that NK cell subsets were associated with the response to immunotherapy.22 The gene discussed is CD274; the disease is melanoma.